In a phase II study of a 10-day regimen of decitabine + venetoclax in older/unfit adults with newly diagnosed AML, a subgroup of patients with FLT3 mutations were enrolled, for whom the treating physician could add a FLT3 inhibitor [56]. This evidence concerns the gene FLT3 and acute myeloid leukemia.